Category Archives: Male Sexual Dysfunction

SAN DIEGO, May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) (www.apricusbio.com) announced today that John P. Mulhall, MD, Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan-Kettering Cancer Center, will present results from an analysis of existing Phase 3 data for Vitaros(R), the Company's lead product candidate for the treatment of erectile dysfunction (ED), at the American Urological Association Annual Meeting which is taking place May 4-8, 2013 in San Diego, CA. The abstract titled, "Vitaros(R) Efficacy and Safety in Viagra(R) Non-Responders with Longer Term Use," will be presented as a moderated poster (#1519) during a session titled "Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy," taking place Tuesday, May 7, 2013 from 8-10 a.m. local time. Dr. Mulhall will give a short oral presentation, which will then be followed by a question and answer period. This analysis evaluated the safety and efficacy of Vitaros(R) after 12 weeks, and longer term use, in men previously unresponsive to phosphodiesterase type 5 (PDE-5) inhibitors, such as Viagra(R) (n=325). Results showed that 200mcg and 300mcg doses of Vitaros(R) improved erections in this population and adverse events (AE) were mild to moderate, similar to those seen … Continue reading →

~ Survey reveals symptoms of vaginal atrophy are causing Canadian couples to avoid sexual intimacy ~ TORONTO, May 6, 2013 /CNW/ - It may not be the most romantic topic for couples to discuss over a candlelit dinner, but it might be a conversation that helps rekindle the romance. A new study reveals that more than six in 10 Canadian women admit they avoid sexual intimacy due to the symptoms of vaginal atrophy (VA), a chronic condition of menopause that needs to be discussed.1 Results from a first-of-its-kind study, CLOSER (CLarifying vaginal atrophy's impact On SEx and Relationships), presented at the Canadian Menopause Society's (SIGMA) first annual Canadian Menopause Conference May 4, 2013, reveals Canadian women and their partners are one of the most likely out of nine countries surveyed to feel VA has caused them to avoid sexual intimacy.1 Affecting more than two million post-menopausal Canadian women,2 VA is a common, treatable condition where the vaginal walls become thin, fragile and inflamed due to a reduction of estrogen.3 Vaginal symptoms include: burning, itching, dryness, irritation and painful intercourse.4 Despite the physical and emotional burden VA causes, couples are still uncomfortable talking about it. It takes two to tango - … Continue reading →

Acupuncture Presentation Part 2 Presentation Acu A Part2 http://apps.who.int/medicinedocs/en/d/Js4926e/5.html This is a link to the WHO report on the conditions that Acupuncture has been cl... By: Dean Scarpinato … Continue reading →

TORONTO, ONTARIO--(Marketwired - May 2, 2013) - Trimel Pharmaceuticals Corporation (TRL.TO) will report its first quarter financial results for the period ended March 31, 2013 on Wednesday, May 8, 2013 after the market closes. Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, May 9, 2013, at 8:30 a.m. Eastern Daylight Time. To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.) or 1- 800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Thursday, May 16, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 3086288#. For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com. About Trimel Trimel Pharmaceuticals Corporation (TRL.TO) - Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed … Continue reading →

San Diego, CA (PRWEB) May 03, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently and is now actively providing expert opinion in view of the recent news on Propecia Lawsuit. On March 28, 2013 B.C. Judge approved a class action lawsuit filed by a man in Supreme Court of British Columbia (Docket S110437) alleging sexual dysfunction from Propecia. Propecia is a pill, manufactured by Merck, for use in males only and indicated for the treatment of male pattern hair loss. It was approved by the FDA in 1997. In the lawsuit plaintiff claims he was prescribed Propecia in 2008 at the age of 25 and months after using the drug he experienced inability to maintain an erection. According to court data updated on March 5, 2013, by the US Judicial Panel on Multi-District Litigation (MDL), there are 140 actions pending in the Propecia MDL (U.S. District Court, Eastern District of New York, MDL 2331 - IN RE: Propecia (Finasteride) Products Liability Litigation). Plaintiffs claim that Merck failed to warn on Propecia side effects that could cause permanent and devastating sexual dysfunction. Taking into consideration the latest developments, AttorneyOne.com updated the website and, now, can actively provide an … Continue reading →

By Casey Walters - May 1, 2013 | Tickers: ARNA, BIIB, BPAX, CELG | 0 Comments Casey is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Bio stocks can be a gamble. When they fall, companies in this particular industry can fall hard, especially if the news is really bad or expectations were hyped beyond reality. A few months ago, Peregrine Pharmaceuticals dropped 78% in one day after the company disclosed that its stellar Phase II data for lung cancer drug bavituximab was not valid. Does that mean bio stocks are a no-go?' Far from it, but in order to do invest effectively, one needs to remember there are a few steps you can take to increase your chances of making money and, more importantly, not losing it all after one press release hits the wires. Spreading your bets is essential. Its easy to be tempted to put money in just one or two names and dream of buying your own island in the Pacific after the company cures cancer. But unless youre incredibly lucky, it doesnt often work out that way. Picking five or even … Continue reading →

TORONTO, ONTARIO--(Marketwired - Apr 30, 2013) - Trimel Pharmaceuticals Corporation (TRL.TO) (the "Company" or "Trimel") proudly announced today that the Company has submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for approval of its bioadhesive intranasal gel testosterone product, indicated for the treatment of testosterone deficiency in men ("CompleoTRT"). The CompleoTRT NDA is supported by efficacy and safety results from 306 patients who participated in the pivotal Phase III study. "This NDA filing is an important achievement for Trimel," said Tom Rossi, President and Chief Executive Officer of Trimel. "If approved, CompleoTRT will provide men suffering from "Low T" with a novel treatment option. CompleoTRT is expected to offer hypogonadal patients the lowest efficacious delivered dose of testosterone in a convenient discreet device, without the risk for secondary transference." The Company expects the CompleoTRT NDA will be subject to a standard review by the FDA, which could be completed as early as the first half of 2014. About CompleoTRT Trimel's most advanced product candidate, CompleoTRT, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment … Continue reading →

Priapus Shot http://www.DoctorsStudio.com Male Sexual Dysfunction and penile enhancement. The Priapus shot offers a very safe and effective treatment to improve penile sensitivi... By: Dr. Lisbeth Roy … Continue reading →

That scene: When Harry Met Sally starring Meg Ryan and Billy Crystal It's been a long time since Meg Ryan performed her famous fake orgasm scene in the movie When Harry Met Sally which was quite outrageous at the time. But it's only now that we are beginning to see the results of some scientific research into why woman and men actually do it. Research has been hindered, no doubt, because of the difficulty in asking people about behaviour that most of them are not proud of and are unlikely to admit to. However according to a research study conducted in 2010 by Erin Cooper, a doctoral student at Temple University in Washington DC, showed that 60 per cent of women had faked an orgasm during intercourse or oral sex, at some point in their lives. The big mystery is why are women pretending? I'll have what she's having: Meg Ryan in When Harry Met Sally Originally the researchers believed it was all about stroking the male ego, but this study found that many of the women said they faked it due to their own fear of intimacy, because they felt insecure about their sexual performance or because they just … Continue reading →

San Francisco, CA (PRWEB) April 24, 2013 Advanced Male Medical Center is proud to announce they have hired Erick Salazar, a 2011 graduate of Everest College, as a Medical Assistant. Salazar joins Advanced Male Medical Centers ever-growing staff that provides state-of-the-art care to the over 7,000 patients they care for in the San Francisco Bay area. Salazar will help to support Advanced Male Medical Centers ever-expanding patient population. Advanced Male Medical Center is a dedicated medical clinic devoted to the needs of men facing erectile dysfunction and premature ejaculation. They treat men that are looking for personal help and ED treatment that have tried other resources such as oral medications or other inhibitors that fail to help them achieve their sexual goals and dreams. The doctors at Advanced Male Medical Center treat each and every patients sexual needs and physical desires on an individual basis. Their trained medical staff has been treating patients ED dysfunction and PE for over 10 years. Because they are dedicated solely to this medical condition, Advanced Male Medical Center far exceeds what an average office visit may be able to offer. They understand the intense need for help and answers to a common and treatable … Continue reading →